Pollens - grasses, sweet vernal grass anthoxanthum odoratum - Biologic Drug Details

Summary for pollens - grasses, sweet vernal grass anthoxanthum odoratum

Tradenames:	1
High Confidence Patents:	0
Applicants:	5
BLAs:	5
Suppliers: see list	4

Pharmacology for pollens - grasses, sweet vernal grass anthoxanthum odoratum

Physiological Effect	Cell-mediated Immunity Increased Histamine Release Increased IgG Production
Established Pharmacologic Class	Standardized Pollen Allergenic Extract
Chemical Structure	Allergens Pollen

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pollens - grasses, sweet vernal grass anthoxanthum odoratum Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pollens - grasses, sweet vernal grass anthoxanthum odoratum Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for pollens - grasses, sweet vernal grass anthoxanthum odoratum Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for the Biologic Drug Targeting Grass Pollens, Including Sweet Vernal Grass (Anthoxanthum odoratum)

Last updated: March 14, 2026

What Are the Key Drivers of Market Growth?

The biologic drug targeting grass pollens, including sweet vernal grass (Anthoxanthum odoratum), operates within the allergy immunotherapy sector. The primary market drivers are:

• Increasing allergy prevalence: Hay fever and pollen allergy rates show an upward trend, especially in North America, Europe, and parts of Asia. Data from the World Allergy Organization (WAO) indicates a global rise in allergic rhinitis, impacting market expansion opportunities[1].

• Growing preference for immunotherapy over antihistamines: Patients and physicians favor targeted immunotherapy for long-term relief, fostering demand for biologic allergy treatments with specific allergen profiles.

• Advances in biologic formulations: Development of recombinant and purified allergen-based biologics improves safety profiles and efficacy, increasing market viability.

• Regulatory landscape: Evolving guidelines, including FDA and EMA approvals for allergen-specific therapies, facilitate drug entry into mature markets with higher reimbursement potential.

• Unmet medical needs: Limited effective chronic treatments for grass pollen allergy create an advanced market for novel biologics.

What Is the Current Market Landscape?

The biologics segment for pollen allergy, specifically targeting grass pollens, is emerging but demonstrates potential for significant growth. Key players are developing products with refined allergen specificity.

Segment	Market Size (2022)	Key Players	Regulatory Status
Grass pollen immunotherapy	Approx. $350 million	Stallergenes, ALK-Abelló	Several products approved in Europe, awaiting US FDA approval
Sweet vernal grass biologics	Early stage	Biotech startups, research institutions	No approved biologics yet; research phase

Factors influencing market growth include:

• Increased adoption of sublingual immunotherapy (SLIT).
• Rising healthcare spending on allergy management.
• Expanding indications to seasonal and perennial allergic rhinitis with grass pollen components.

What Are the Financial Projections?

Forecasts suggest robust growth for biologics targeting grass pollen allergies over the next decade:

Year	Estimated Market Size	CAGR (Compound Annual Growth Rate)	Notes
2023	$400 million	–	Market stabilization as new entrants prepare for launch
2025	$600 million	15%	Growth driven by regulatory approvals and increased adoption
2030	$1.8 billion	22%	Cumulative effect of pipeline approvals and expanding indications

The biologic allergy market overall is projected to reach approximately $9.4 billion globally by 2030[2], with grass pollen-specific biologics constituting a significant share due to prevalence.

How Do Regulatory and Reimbursement Policies Affect Trajectory?

• Regulatory approval pathways: Biologics targeting grass pollens face accelerated pathways in some jurisdictions, such as EMA's centralized procedure; US FDA's biologics license applications (BLA) remain competitive but challenging.

• Reimbursement challenges: High development costs and pricing negotiations influence profitability. Reimbursement policies favor biologics with demonstrated long-term benefits and cost-effectiveness, with payer coverage increasing as data solidifies.

What Are the Challenges and Risks?

• Pipeline uncertainty: Lack of mature products limits current revenue streams, with most biologics in late-stage development or clinical trials.

• Market penetration: Competition from traditional allergy immunotherapies and emerging small-molecule or combination therapies may impede adoption.

• Manufacturing costs: Complex production processes for biologics result in high costs, affecting pricing strategies.

What Is the Competitive Outlook?

Several biotech companies are developing biologics with allergen-specific approaches:

• Stallergenes Greer: markets Grazax (grass pollen SLIT tablet).
• ALK-Abelló: expanding pollen immunotherapy products.
• Emerging startups: focus on recombinant allergen biologics targeting specific pollens.

Their success depends on regulatory approvals, demonstrated efficacy, and payer acceptance.

Key Takeaways

• The biologic market for grass pollen allergies, including sweet vernal grass, is in early stages but poised for growth driven by rising allergy prevalence, advances in biologic formulations, and favorable regulatory environments.
• Market projections estimate a compound annual growth rate of approximately 15-22% from 2023-2030.
• Challenges include pipeline uncertainties, high manufacturing costs, and competition from established therapies.
• Regulatory approval processes and reimbursement policies significantly influence market entry and profitability.
• Key players are focusing on allergen-specific biologics with long-term efficacy benefits.

FAQs

1. What factors primarily influence the market growth for grass pollen biologics?
Increasing allergy prevalence, patient preference for targeted immunotherapy, advances in biologic technology, and supportive regulatory pathways contribute most to market growth.

2. Which regions offer the most promising opportunities?
North America and Europe lead due to high allergy prevalence and mature healthcare systems. Asian markets show growth potential due to rising allergy awareness.

3. What are the main regulatory hurdles?
Obtaining approval requires demonstrating safety, efficacy, and manufacturing consistency. US FDA approval for novel biologics remains a significant hurdle, though pathways like Fast Track or Breakthrough Therapy can facilitate process advancement.

4. How does reimbursement affect commercial potential?
Reimbursement policies that favor long-term cost-effectiveness can accelerate adoption, while high costs and uncertain coverage delay market penetration.

5. Which companies are leading development efforts?
Stallergenes Greer, ALK-Abelló, and emerging biotech startups focusing on recombinant allergen biologics dominate the landscape.

---

References

[1] World Allergy Organization. (2021). Global allergy prevalence report.
[2] Milliman. (2022). Global biologics immunotherapy market forecast, 2023–2030.